Singapore markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
62.96+0.51 (+0.82%)
At close: 04:00PM EDT
62.80 -0.16 (-0.25%)
After hours: 07:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close62.45
Bid62.95 x 3100
Ask63.00 x 1100
Day's range62.15 - 62.99
52-week range57.17 - 74.12
Avg. volume6,901,254
Market cap78.971B
Beta (5Y monthly)0.35
PE ratio (TTM)19.25
EPS (TTM)3.27
Earnings date26 Oct 2022 - 31 Oct 2022
Forward dividend & yield2.92 (4.74%)
Ex-dividend date14 Sept 2022
1y target est69.79
  • Motley Fool

    3 Healthcare Stocks With High Profit Margins

    If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.

  • Business Wire

    Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency

    FOSTER CITY, Calif., August 09, 2022--Gilead Sciences, Inc. (Nasdaq: GILD), GLAAD, the Human Rights Campaign (HRC), the National Black Justice Coalition (NBJC), the National Center for Lesbian Rights (NCLR) and NMAC today announced immediate action in response to the emerging monkeypox virus (MPV) outbreak, which is disproportionately impacting the LGBTQ+ community, particularly men who have sex with men (MSM), as well as those who are living with HIV. Gilead will provide up to $5 million in glo

  • Motley Fool

    2 Reasons This Beaten-Down Stock Could Be About to Rebound

    Gilead Sciences (NASDAQ: GILD) has kept its revenue and earnings growing in the past two years -- if ever so slightly -- largely thanks to Veklury, its COVID-19 therapy. Gilead Sciences' revenue rose by only about 1% year over year to $6.3 billion during the period. Excluding sales of Veklury, which dropped by 46% year over year to $445 million, Gilead Sciences' revenue for the quarter grew by a more impressive and respectable (by industry standards) 7%.